MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

64.72 +0.57 (+0.89%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
91 92 Next >
News headline image
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
Bristol Myers Squibb’s second quarter results were marked by strong contributions from its growth portfolio, leading to a positive market reaction. Managemen... 
Via StockStory
Topics Earnings
News headline image
Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗
Growth portfolio now drives 60% of revenue as Eliquis surges 21%. 
Via The Motley Fool
Topics Earnings
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Via Chartmill
Bristol-Myers Squibb (NYSE:BMY) Surges on Q2 Earnings Beat, Raises Full-Year Guidance ↗
Via Chartmill
Topics Earnings
Bristol Myers Squibb Co (NYSE:BMY): A High Yield Dividend Stock Backed by Strong Profitability ↗
Via Chartmill
News headline image
Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That ↗
Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Q2 Earnings Call Highlights ↗
Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenue of approximately $13 billion, up 5% from a year earlier, as growth in newer products offset declines across its legacy portfolio.... 
Via MarketBeat
Topics Earnings
News headline image
BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on ... 
Via StockStory
News headline image
Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗
Growth portfolio now drives 60% of revenue as Eliquis surges 21%. 
Via The Motley Fool
Topics Earnings
News headline image
Why Bristol Myers Squibb Stock Topped the Market on Thursday ↗
It notched convincing beats on analyst estimates with its second-quarter performance. 
Via The Motley Fool
News headline image
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About ↗
Things are going well for the pharmaceutical giant. 
Via The Motley Fool
Topics Lawsuit
News headline image
Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on ... 
Via StockStory
News headline image
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday before market open. Here’s what to look for. Bristol-Myers ... 
Via StockStory
News headline image
This Healthcare Leader Just Made a Bet on Artificial Intelligence (AI): Time to Buy the Stock? ↗
Bristol Myers keeps making moves to establish a strong foundation for the future. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
My 3 Favorite Artificial Intelligence (AI) Stocks to Buy Right Now ↗
We may still be in the early innings of the AI revolution, and these companies could be among the biggest winners. 
Via The Motley Fool
Topics Artificial Intelligence Electric Vehicles
News headline image
Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now ↗
As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal. 
Via MarketBeat
Topics Economy
News headline image
Israel "Izzy" Englander Increased His Position in This Pharma Stock by 780%. Does He Know Something Wall Street Doesn't? ↗
Analysts aren't nearly as bullish about Bristol Myers Squibb as this billionaire hedge fund manager is. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer ↗
Sometimes you need to look beyond the numbers to get the full story. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have... 
Via StockStory
News headline image
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗
Could it become as successful in this niche as it was in the coronavirus vaccine market? 
Via The Motley Fool
News headline image
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
From Bristol Myers Squibb
Via Business Wire
News headline image
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb ↗
Drug pricing matters, but pipelines matter even more. 
Via The Motley Fool
Topics Government Intellectual Property
News headline image
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
They may not remain cheap for too much longer. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List) ↗
It doesn't get much more dependable and lucrative than the healthcare industry. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know. ↗
This big pharma stock looks attractive for income investors -- but it comes with some risk. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vanguard Is Bullish on Value Stocks and Fixed Income. Are These 2 ETFs a Good Buy? ↗
Strong productivity gains from AI -- and lower inflation -- could be good news for these Vanguard ETFs. 
Via The Motley Fool
Topics Artificial Intelligence Bonds ETFs
News headline image
2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
91 92 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story